|Grant Affiliation:||Ho: Ibalizumab for HIV Prevention|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2012-03-01|
|Study Made Public:||2013-02-13|
In vitro neutralization activity of ibalizumab and ibalizumab variants
CAVD 353 is a monoclonal antibody characterization study to evaluate the neutralization activity of the monoclonal antibody, Ibalizumab, and Ibalizumab variants.
Sign in to see full information about this study and to download study data.
ProductsNo Products used in study
No non-integrated data is available for this study.